25 October 2018

New iLite® ADCC Product Line

New Product Line - iLite® Assay Ready Cells for determination of ADCC activity

Svar Life Science AB today announced the availability of a new product line, the iLite® ADCC Activity Assay product line. The new iLite® ADCC Activity Assays enables measurement of Antibody-dependent cell-medicated cytotoxicity (ADCC) in a straight forward, sensitive and reproducible manner.

The new iLite® ADCC Activity Assay product line enables measurement of Antibody-dependent cell-medicated cytotoxicity (ADCC) in a straight forward, sensitive and reproducible manner. The new product line broadens Svar Life Sciences´ offering of cell-based assays and complement the product and service solutions already appreciated by pharmaceutical clients.

Jörgen Dahlström, Chief Business Officer, Svar Life Science, says:

"Antibody therapy has been proven to be highly powerful for cancer treatment and an important mechanism is the ability of antibody drugs to kill targeted tumour cells by Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). It is our aim to launch new and unique products within this field since the addition complements our existing assay solutions, and cements Svar Life Science position as a supplier of products and services for the pharma industry”.

Product details:

The iLite® ADCC Activity Set contains 3 different genetically modified cell lines; a reporter Effector cell, a positive Target cell and a negative Target cell. All three products can be supplied individually or in combination as iLite® ADCC Activity Set. These Activity sets enables measurements of an anti-targeted drug’s ability to induce ADCC, does not require any cell culturing and allow results to be read within 4 hours. In addition, the Effector cells, which can be used with any Target cell, include a normalization readout which can be used to adjust for differences in cell counts.

Target cells for HER2. EGFR and membrane bound TNF- alpha will be the first to be launched, followed by shortly by CD20 Target cells.

The unique set-up of Assay Ready effector cells and matched target cells, engineered to work optimally together, gives unparalleled sensitivity and with the launch of the first products in the iLite® ADCC product line, we can successfully assist clients with accelerating their drug discovery and development programs” adds Therese Segerstein, Product Manager Cell Based Assays.

As all iLite® cell lines, the ADCC products are provided as Assay Ready Cells and can be set up and performed through our bioanalytical service laboratory in compliance with GLP and GCP.

For further information please contact:

Therese Segerstein
Product Manager Cell Based Assays
T +46 40 643 49 21
E therese.segerstein@svarlifescience.com

Camilla Duborn
Senior Director Sales EMEA & APAC
T +46 40 53 76 11
E camilla.duborn@svarlifescience.com

Based on a reporter gene assay format, the iLite technology can be modified and adapted for applications during the whole drug development cycle as well as for monitoring of biological drugs

Read more about how the iLite technology eliminates many of the limitations of conventional cell-based assays